Vetter ramps up global clinical manufacturing push with major US & Europe expansion
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The first of four planned modules at the new plant is expected to come online by summer 2026
The facility is expected to become operational by FY2028-29
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Subscribe To Our Newsletter & Stay Updated